MOUD Naltrexone LA denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for moud naltrexone la are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Long-Acting Naltrexone as Duplicate Therapy — and Why You Can Appeal

A duplicate-therapy denial for long-acting injectable naltrexone (commonly known by the brand name Vivitrol) from Cigna typically arises when the plan's automated review flags another opioid use disorder medication — most commonly buprenorphine — as already active or recently active on the patient's profile. Because buprenorphine and naltrexone work through fundamentally different pharmacological mechanisms and serve different clinical populations, a duplicate-therapy classification that treats them as interchangeable is clinically inaccurate and subject to appeal.

## Why This Denial Is Appealable

Naltrexone is an opioid antagonist with no opioid agonist activity. It is FDA-approved for opioid use disorder (OUD) and operates through an entirely distinct mechanism from buprenorphine (a partial agonist) or methadone (a full agonist). A plan that denies long-acting naltrexone as "duplicate" of buprenorphine is making a clinical determination that conflicts with the FDA's approval of both drugs as distinct treatment options — and with ASAM and SAMHSA clinical practice guidance supporting individualized medication selection.

Federal parity law (MHPAEA) is an additional basis: if Cigna does not apply duplicate-therapy logic to deny medications for other chronic conditions with multiple approved pharmacological classes, applying it to OUD medications is a potential parity violation.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal within the deadline on the denial letter. Request a peer-to-peer review between the prescriber and Cigna's medical director.
• External review: After exhausting internal review, request independent external review under ACA §2719 — typically within four months of the internal denial notice.
• Expedited review: If the patient faces urgent clinical risk without the medication, the prescriber can request an expedited determination.

## Concrete Appeal Steps

1. Obtain the denial letter and confirm which drug Cigna is citing as the "duplicate." 2. Pull Cigna's published coverage policy for long-acting injectable naltrexone — available on cigna.com or through the treating provider portal. 3. Have the prescriber document why naltrexone is the clinically appropriate choice for this patient and why the allegedly duplicate drug is either not indicated or was previously tried and is not suitable. 4. Compile the documentation package below and file the internal appeal.

## Documentation to Gather

• Diagnosis confirmation: DSM-5 moderate-to-severe OUD diagnosis with assessment date.
• Clinical rationale for naltrexone specifically: Prescriber note explaining why long-acting naltrexone is the appropriate MOUD choice for this patient — including any prior buprenorphine or methadone history with outcomes, or clinical reasons those options are not appropriate.
• Pharmacological distinction letter: Prescriber or clinical letter explaining that naltrexone and buprenorphine are mechanistically distinct, FDA-approved for the same indication through different pathways, and are not duplicates.
• Applicable treatment history: Dates and outcomes of any prior MOUD trials.
• Criteria-mapping table: Each Cigna policy criterion in one column; the chart-based evidence in the other.

## Criteria-Mapping Structure

For a duplicate-therapy appeal, the central mapping is: Cigna's definition of "duplicate" → evidence that long-acting naltrexone and the flagged drug do not share the same mechanism or clinical profile. Supplement with the FDA prescribing label for each drug to reinforce the pharmacological distinction.